Despite limited evidence, RhoB [226] and RhoC [227] as well as other Rho GTPase associated interactions, including melanoma cell adhesion molecule (MCAM) [228] or regulator of chromosome condensation 2 (RCC2) [229], represent biomarkers with potential in gynecologic cancer therapy. Here, RCC2 is linked to female reproductive organ cancer.